Curaleaf Presses Aurora Shareholders to Tender by Dec 1 and Hosts Sept 17 Q&A
CURLF sits 86% above its 52-week low of $5.4.
Summary
Curaleaf sent a letter to Aurora shareholders urging them to tender shares by December 1, 2026, and announced a live Q&A with CEO Boris Jordan on September 17. The letter reiterates the US$4.00 offer and adds new comparative performance data and dilution criticism.
Key Events · M&A and Partnerships · CURLF
-
Shareholder Letter and Tender Deadline
A December 1, 2026 deadline has been set for Aurora shareholders to tender, with the US$4.00 per share offer (a 45% premium to August 10 VWAP) reiterated.
-
Live Q&A with CEO Boris Jordan
A live shareholder webcast is scheduled for Thursday, September 17, 2026 at 10:30 a.m. ET, where Jordan will address Aurora shareholders directly.
-
Comparative Performance Data
In H1 2026, Curaleaf shares rose ~50% while Aurora fell ~34%; over four quarters ended June 30, 2026, Aurora's net revenue and adjusted EBITDA declined 14% and 78% respectively.
-
Dilution Criticism
Aurora raised over US$400 million through dilutive equity issuances, including sales as low as US$2.60 per share in July 2026 — a 35% discount to Curaleaf's offer.
Analysis · CURLF · Life Sciences
The hostile takeover campaign for Aurora Cannabis is escalating, with a direct shareholder letter and a live Q&A event. The US$4.00 per share offer (a 45% premium to the August 10 VWAP) is reiterated, but new tactical pressure is added: a December 1, 2026 tender deadline, a September 17 shareholder Q&A with CEO Boris Jordan, and fresh comparative data showing Aurora's revenue and adjusted EBITDA declining 14% and 78% respectively over the trailing four quarters. The filing also highlights Aurora's dilutive equity issuances totaling over US$400 million, including sales as low as US$2.60 per share in July 2026 — a 35% discount to Curaleaf's offer. This is a material escalation in the proxy fight, aimed at swaying Aurora shareholders ahead of the tender deadline.
How filings like this one have moved
In the 30 days to Sep 15, 2026, 29.9% of the 1678 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.25%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, CURLF was trading at $10.06 on OTC in the Life Sciences sector, with a market capitalization of approximately $2.7B. The 52-week trading range was $5.40 to $15.15. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.